Cargando…

2492. Implementation of a Hepatitis C Referral Workflow: A Pilot Program

BACKGROUND: Direct-acting antiviral (DAA) treatment for hepatitis C viral infection (HCV) is typically initiated in the outpatient setting. Currently at Oregon Health and Science University (OHSU) hospital, there is no standardized method of connecting hospitalized patients who test positive for HCV...

Descripción completa

Detalles Bibliográficos
Autores principales: Chun, Katherine, Lau, Gary, Lee, Jenica, Ham, YoungYoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678210/
http://dx.doi.org/10.1093/ofid/ofad500.2110
_version_ 1785150308583735296
author Chun, Katherine
Lau, Gary
Lee, Jenica
Ham, YoungYoon
author_facet Chun, Katherine
Lau, Gary
Lee, Jenica
Ham, YoungYoon
author_sort Chun, Katherine
collection PubMed
description BACKGROUND: Direct-acting antiviral (DAA) treatment for hepatitis C viral infection (HCV) is typically initiated in the outpatient setting. Currently at Oregon Health and Science University (OHSU) hospital, there is no standardized method of connecting hospitalized patients who test positive for HCV with outpatient care for treatment. As a result, patients are infrequently referred. We created and implemented a pharmacist-led workflow to evaluate patients and officially refer admitted patients to outpatient care. The goal is to increase the rate of patients who attend follow-up appointments that address HCV diagnosis and treatment after a hospitalization, and increase the rate of patients who are treated. METHODS: The pharmacist-led workflow was implemented from October through December 2021. Pre- and post-implementation (Pre-I and post-I) data was collected and analyzed. Hepatitis C positive patients were identified and assessed for willingness to be treated. If willing, assessment was completed while inpatient and an official outpatient referral was placed. The data includes patients who attended an appointment (primary outcome) and patients who were prescribed a DAA (secondary outcome). [Figure: see text] RESULTS: In pre-I, 44 patients were screened and 18 patients met inclusion. In post-I, 75 patients were screened and 33 met inclusion. Fourteen patients (33%) in post-I and 4 patients (22%) in pre-I were referred to hepatology. Nine patients (50%) in pre-I and 6 patients (14%) in post-I attended a clinic appointment within 3 months. Three patients (17%) in pre-I and 5 patients (12%) in post-I were prescribed a DAA within 3 months. However, of the referred patients, 2 patients in pre-I and 3 patients in post-I attended an appointment within 3 months. No patients in pre-I and 1 patient in post-I were prescribed a DAA. In both pre- and post-I, 33% of those who attended an appointment received a prescription for a DAA within three months. [Figure: see text] [Figure: see text] [Figure: see text] CONCLUSION: A pharmacist-led HCV referral workflow increased the rate of referrals to hepatology. However, this increase in referrals did not correspond with a substantial increase in appointments or receipt of a prescription. While the workflow increased referrals, it did not increase patient receipt of DAAs. More intensive interventions may be needed to reach this population. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-10678210
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106782102023-11-27 2492. Implementation of a Hepatitis C Referral Workflow: A Pilot Program Chun, Katherine Lau, Gary Lee, Jenica Ham, YoungYoon Open Forum Infect Dis Abstract BACKGROUND: Direct-acting antiviral (DAA) treatment for hepatitis C viral infection (HCV) is typically initiated in the outpatient setting. Currently at Oregon Health and Science University (OHSU) hospital, there is no standardized method of connecting hospitalized patients who test positive for HCV with outpatient care for treatment. As a result, patients are infrequently referred. We created and implemented a pharmacist-led workflow to evaluate patients and officially refer admitted patients to outpatient care. The goal is to increase the rate of patients who attend follow-up appointments that address HCV diagnosis and treatment after a hospitalization, and increase the rate of patients who are treated. METHODS: The pharmacist-led workflow was implemented from October through December 2021. Pre- and post-implementation (Pre-I and post-I) data was collected and analyzed. Hepatitis C positive patients were identified and assessed for willingness to be treated. If willing, assessment was completed while inpatient and an official outpatient referral was placed. The data includes patients who attended an appointment (primary outcome) and patients who were prescribed a DAA (secondary outcome). [Figure: see text] RESULTS: In pre-I, 44 patients were screened and 18 patients met inclusion. In post-I, 75 patients were screened and 33 met inclusion. Fourteen patients (33%) in post-I and 4 patients (22%) in pre-I were referred to hepatology. Nine patients (50%) in pre-I and 6 patients (14%) in post-I attended a clinic appointment within 3 months. Three patients (17%) in pre-I and 5 patients (12%) in post-I were prescribed a DAA within 3 months. However, of the referred patients, 2 patients in pre-I and 3 patients in post-I attended an appointment within 3 months. No patients in pre-I and 1 patient in post-I were prescribed a DAA. In both pre- and post-I, 33% of those who attended an appointment received a prescription for a DAA within three months. [Figure: see text] [Figure: see text] [Figure: see text] CONCLUSION: A pharmacist-led HCV referral workflow increased the rate of referrals to hepatology. However, this increase in referrals did not correspond with a substantial increase in appointments or receipt of a prescription. While the workflow increased referrals, it did not increase patient receipt of DAAs. More intensive interventions may be needed to reach this population. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2023-11-27 /pmc/articles/PMC10678210/ http://dx.doi.org/10.1093/ofid/ofad500.2110 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Chun, Katherine
Lau, Gary
Lee, Jenica
Ham, YoungYoon
2492. Implementation of a Hepatitis C Referral Workflow: A Pilot Program
title 2492. Implementation of a Hepatitis C Referral Workflow: A Pilot Program
title_full 2492. Implementation of a Hepatitis C Referral Workflow: A Pilot Program
title_fullStr 2492. Implementation of a Hepatitis C Referral Workflow: A Pilot Program
title_full_unstemmed 2492. Implementation of a Hepatitis C Referral Workflow: A Pilot Program
title_short 2492. Implementation of a Hepatitis C Referral Workflow: A Pilot Program
title_sort 2492. implementation of a hepatitis c referral workflow: a pilot program
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678210/
http://dx.doi.org/10.1093/ofid/ofad500.2110
work_keys_str_mv AT chunkatherine 2492implementationofahepatitiscreferralworkflowapilotprogram
AT laugary 2492implementationofahepatitiscreferralworkflowapilotprogram
AT leejenica 2492implementationofahepatitiscreferralworkflowapilotprogram
AT hamyoungyoon 2492implementationofahepatitiscreferralworkflowapilotprogram